MEM

Turkey registration unlocks commercial sales under the ITL distribution agreement in a 165-clinic, 75k-cycle/year market; first order of 100 cartridges + 2 consoles completed, with distributor training in place to drive clinic adoption. However, timing and magnitude of future orders remain clinic-dependent and uncertain.

MEM has secured a three-year Nordic distribution agreement worth €526,500 (~AUD 880k at ~1.67 FX) with immediate first-quarter order, expanding Felix™ commercial presence to nine European countries. This is a steady geographic roll-out milestone, but the contracted value is modest relative to the company's $1.18B cash balance and 15m market cap, suggesting the deal is strategic credibility rather than near-term revenue inflection.

(interpretation unavailable)

Vietnam regulatory clearance on schedule unlocks a A$530,000 two-year exclusive distribution agreement with TMSC Vietnam, with a 600-cartridge commercial order now triggered and first clinical pregnancy already reported. This represents tangible execution against the June 2026 market-entry roadmap in a growing Southeast Asia fertility market.